Effect of intravenous metoprolol on reversible obstructive airways disease

Thomas A. Abraham, Faysal M. Hasan, Paul E. Fenster, Frank I. Marcus

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


We gave increasing doses of metoprololintravenously to seven subjects with stable chronic obstructive pulmonary disease (COPD) who were also receiving their usual bronchodilators. Six of the seven tolerated up to 0.2 mg/kg metoprolol without adverse effects, although there were declines in forced expiratory volume in 1 sec (FEV1) At 0.15 mg/kg mean FEV1 fell 12% (p < 0.025), and at 0.2 mglkg mean decline in FEV1 was 15% (p < 0.01). These findings suggest that 0.2 mg/kg metoprolol may be given intravenously to most patients with COPD in addition to previously administered bronchodilators without precipitating clinically significant adverse effects. Any side effects that develop can be reversed by beta agonists.

Original languageEnglish (US)
Pages (from-to)582-587
Number of pages6
JournalClinical Pharmacology and Therapeutics
Issue number5
StatePublished - May 1981

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Effect of intravenous metoprolol on reversible obstructive airways disease'. Together they form a unique fingerprint.

Cite this